Get started
SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0QN1 chart


Full chart

0QN1 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪104.94 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
1.82
Basic EPS (TTM)
5.92 CHF
Net income (FY)
‪54.78 M‬ CHF
Revenue (FY)
‪103.41 M‬ CHF
Shares float
‪9.32 M‬
Beta (1Y)
−0.27

Employees


Employees (FY)
44
Change (1Y)
−1 −2.22%
Revenue / Employee (1Y)
‪2.31 M‬ CHF
Net income / Employee (1Y)
‪1.22 M‬ CHF

About SANTHERA N


Sector
Health Technology
CEO
Dario Eklund
Headquarters
Pratteln
Website
santhera.com
Founded
1998
ISIN
CH1276028821
FIGI
BBG00JYV5H90
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0QN1 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0QN1 is 11.28 CHF — it has increased by 7.84% in the past 24 hours. Watch SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stocks are traded under the ticker 0QN1.
0QN1 stock has risen by 14.29% compared to the previous week, the month change is a 37.06% rise, over the last year SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) has showed a 12.35% increase.
We've gathered analysts' opinions on SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) future price: according to them, 0QN1 price has a max estimate of 25.00 CHF and a min estimate of 20.00 CHF. Watch 0QN1 chart and read a more detailed SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock forecast: see what analysts think of SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) and suggest that you do with its stocks.
0QN1 reached its all-time high on Feb 19, 2018 with the price of 292.50 CHF, and its all-time low was 5.30 CHF and was reached on Dec 7, 2022. View more price dynamics on 0QN1 chart.
See other stocks reaching their highest and lowest prices.
0QN1 stock is 8.33% volatile and has beta coefficient of −0.27. Track SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock price on the chart and check out the list of the most volatile stocks — is SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) there?
Today SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) has the market capitalization of ‪138.49 M‬, it has increased by 8.39% over the last week.
Yes, you can track SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) financials in yearly and quarterly reports right on TradingView.
SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) revenue for the last half-year amounts to ‪14.10 M‬ CHF, despite the estimated figure of ‪5.60 M‬ CHF. In the next half-year revenue is expected to reach ‪13.70 M‬ CHF.
0QN1 net income for the last half-year is ‪−15.26 M‬ CHF, while the previous report showed ‪78.12 M‬ CHF of net income which accounts for −119.54% change. Track more SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) financial stats to get the full picture.
No, 0QN1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 44.00 employees. See our rating of the largest employees — is SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) EBITDA is ‪57.08 M‬ CHF, and current EBITDA margin is 51.81%. See more stats in SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) financial statements.
Like other stocks, 0QN1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) stock shows the buy signal. See more of SANTHERA PHARMACEUTICALS HOLDING AG CHF0.1 (POST CONS) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.